Glaxosmithkline - Pharma mit Dividende (Seite 2)
eröffnet am 15.07.10 17:19:04 von
neuester Beitrag 24.04.24 19:26:43 von
neuester Beitrag 24.04.24 19:26:43 von
Beiträge: 1.037
ID: 1.158.829
ID: 1.158.829
Aufrufe heute: 4
Gesamt: 128.828
Gesamt: 128.828
Aktive User: 0
ISIN: GB00BN7SWP63 · WKN: A3DMB5 · Symbol: GS71
19,190
EUR
+0,29 %
+0,055 EUR
Letzter Kurs 16:30:43 Tradegate
Neuigkeiten
24.04.24 · dpa-AFX Analysen |
24.04.24 · dpa-AFX Analysen |
18.04.24 · dpa-AFX |
08.04.24 · dpa-AFX Analysen |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +25,00 | |
| 56,69 | +20,00 | |
| 0,6400 | +18,52 | |
| 491,30 | +17,07 | |
| 1,1100 | +15,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 92,06 | -19,84 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 | |
| 0,7000 | -61,96 |
Beitrag zu dieser Diskussion schreiben
Feedback
Gsk scheint sich langsam aus dem Winterschlaf aufzuwachen 🧙♂️🐰🕺
Bin mit meinem Kauf mittlerweile zufrieden, aber lange hat's gedauert.
Antwort auf Beitrag Nr.: 75.215.147 von Pacific1 am 04.02.24 08:04:08Nachhaltig !!! 🤑🤫
Dennoch sieht es hier gut aus, ganz im Gegenteil zur Deutschland AG. 🤒😬.
Antwort auf Beitrag Nr.: 75.215.966 von mp2019 am 04.02.24 13:04:48Ja, ja die US Klageindustrie, will jedem das Hemd und die Unterhose ausziehen, der Kohle verdient 😡😡😡😡. Verdammte Bande 🤒🚾🚾🚾
Trading Spotlight
GSK's RSV vaccine success makes its shares look cheap
At the close of 2023, GSK had 71 vaccines and speciality medicines in clinical development, including 18 in the third and final trial stage. This fact alone should go some way towards assuaging pipeline worries. The group now anticipates 2024 revenue growth of 5-7 per cent and adjusted operating profit growth of 7-10 per cent. In the longer term, it will have to contend with the loss of patent exclusivity on dolutegravir, one of the key treatments in its HIV franchise.
The majority of this impact will be seen in 2029 and 2030 – although management has stated that it expects operating margins to remain “broadly stable through this period”. While it’s clear that this so-called 'patent cliff' will remain tricky, it’s not going to negate the very real progress GSK has made elsewhere in its portfolio.
In terms of downside risk, there is the matter of the ongoing US litigation around heartburn drug Zantac, and although the company has settled many of the cases, there is another hearing scheduled imminently. At this point, there’s no way to estimate the cost of resolving the saga, but with shares trading on just 10 times forward earnings for 2024, we’d argue GSK looks cheap for a company on the up. Buy.
https://www.investorschronicle.co.uk/news/2024/01/31/gsk-s-r…
At the close of 2023, GSK had 71 vaccines and speciality medicines in clinical development, including 18 in the third and final trial stage. This fact alone should go some way towards assuaging pipeline worries. The group now anticipates 2024 revenue growth of 5-7 per cent and adjusted operating profit growth of 7-10 per cent. In the longer term, it will have to contend with the loss of patent exclusivity on dolutegravir, one of the key treatments in its HIV franchise.
The majority of this impact will be seen in 2029 and 2030 – although management has stated that it expects operating margins to remain “broadly stable through this period”. While it’s clear that this so-called 'patent cliff' will remain tricky, it’s not going to negate the very real progress GSK has made elsewhere in its portfolio.
In terms of downside risk, there is the matter of the ongoing US litigation around heartburn drug Zantac, and although the company has settled many of the cases, there is another hearing scheduled imminently. At this point, there’s no way to estimate the cost of resolving the saga, but with shares trading on just 10 times forward earnings for 2024, we’d argue GSK looks cheap for a company on the up. Buy.
https://www.investorschronicle.co.uk/news/2024/01/31/gsk-s-r…
Antwort auf Beitrag Nr.: 75.210.566 von graueeminenz77 am 02.02.24 19:16:03Das tut sie :-)
GSK plc (GSK.L) erhöht die vierteljährliche Dividende um 14.29% von 0.14£ auf 0.16£ pro Aktie.
Ex-Div-Tag wird am 22.02.2024 sein.
Zahl-Tag wird am 11.04.2024 sein.
https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-…
GSK plc (GSK.L) erhöht die vierteljährliche Dividende um 14.29% von 0.14£ auf 0.16£ pro Aktie.
Ex-Div-Tag wird am 22.02.2024 sein.
Zahl-Tag wird am 11.04.2024 sein.
https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-…
Ich hoffe Mal dass die Dividende steigt 👍
Buy 👍🤑
Es läuft jetzt obwohl "Herabstufung" ganz gut 🤞. GSK forever ... ich verkaufe nichts vom Bestand. Dividende ist vollkommen okay und der Kurs ist mir auf dem Niveau+/- 3 Euro total Schnuppe 😇?. Alles Gute im Neuen Jahr für allen "Mitstreiter" 😉
Durchsuchen
18.04.24 · dpa-AFX · Bayer |
20.03.24 · dpa-AFX · GSK |
19.03.24 · wallstreetONLINE Redaktion · Morphosys |
18.03.24 · wallstreetONLINE Redaktion · Pfizer |
17.03.24 · dpa-AFX · CureVac |
09.03.24 · wallstreetONLINE Redaktion · L'Oreal |
20.02.24 · wallstreetONLINE Redaktion · Medtronic |
31.01.24 · dpa-AFX · GSK |
31.01.24 · dpa-AFX · Advanced Micro Devices |
